Drug Profile
BRM 421
Alternative Names: BRM 421; PDSPLatest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator MacKay Memorial Hospital
- Developer BRIM Biotechnology
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Dry eyes
- No development reported Alopecia; Corneal injuries; Osteoarthritis
Most Recent Events
- 27 Feb 2023 Phase-III clinical trials in Dry eyes (In the elderly, In adults) in USA (Ophthalmic) (NCT05695781)
- 23 May 2022 BRIM Biotechnology announces intention to submit NDA to US FDA for Dry eye syndrome in 2026 (BRIM Biotechnology pipeline, May 2022)
- 17 May 2022 BRIM Biotechnology Inc intends to initiate phase III clinical trial for Dry eye syndrome (DES) in later 2022